相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Population Pharmacokinetic Study of Memantine: Effects of Clinical and Genetic Factors
Muriel Noetzli et al.
CLINICAL PHARMACOKINETICS (2013)
Discontinuing Donepezil or Starting Memantine for Alzheimer's Disease
Lon S. Schneider
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease
Robert Howard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Paraoxonase 1 Gene Polymorphisms Do Not Influence the Response to Treatment in Alzheimer's Disease
A. Klimkowicz-Mrowiec et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2011)
Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?
Laura Magliulo et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors
Caterina Chianella et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Role of organic cation transporters in drug-induced toxicity
Giuliano Ciarimboli
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
Genetics of Alzheimer's Disease: An Insight Into Presenilins and Apolipoprotein E Instigated Neurodegeneration
M. Obulesu et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2011)
Active Site Gating and Substrate Specificity of Butyrylcholinesterase and Acetylcholinesterase: Insights from Molecular Dynamics Simulations
Lei Fang et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2011)
Apolipoprotein E in Alzheimer's disease and other neurological disorders
Philip B. Verghese et al.
LANCET NEUROLOGY (2011)
Epidemiology of Alzheimer disease
Christiane Reitz et al.
NATURE REVIEWS NEUROLOGY (2011)
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)
Laura M. Hodges et al.
PHARMACOGENETICS AND GENOMICS (2011)
Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease
N. R. Cutler et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis
Martin R. Farlow et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Changes in cognitive functions of patients with dementia of the Alzheimer type following long-term administration of donepezil hydrochloride: Relating to changes attributable to differences in apolipoprotein E phenotype
Kiyoshi Kanaya et al.
GERIATRICS & GERONTOLOGY INTERNATIONAL (2010)
Current status on Alzheimer disease molecular genetics: from past, to present, to future
Karolien Bettens et al.
HUMAN MOLECULAR GENETICS (2010)
Neurochemical basis for symptomatic treatment of Alzheimer's disease
Paul T. Francis et al.
NEUROPHARMACOLOGY (2010)
The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects
Kristel Sleegers et al.
TRENDS IN GENETICS (2010)
Identification of polymorphisms in the 3′-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism
L. Oleson et al.
XENOBIOTICA (2010)
Variability of AChE, BChE, and ChAT Genes in the Late-Onset Form of Alzheimer's Disease and Relationships With Response to Treatment With Donepezil and Rivastigmine
Renato Scacchi et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS (2009)
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance Part I
Shu-Feng Zhou
CLINICAL PHARMACOKINETICS (2009)
Memantine in Moderately-Severe-to-Severe Alzheimer's Disease A Postmarketing Surveillance Study
Francesca Clerici et al.
DRUGS & AGING (2009)
Similar Rivastigmine Pharmacokinetics and Pharmacodynamics in Japanese and White Healthy Participants Following the Application of Novel Rivastigmine Patch
Gilbert Lefevre et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease
O. L. Lopez et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2009)
Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease
Alberto Pilotto et al.
NEUROLOGY (2009)
The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test
Beatrice Oneda et al.
PHARMACOGENETICS AND GENOMICS (2009)
Long-term course and effectiveness of combination therapy in Alzheimer disease
Alireza Atri et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2008)
Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline
Parminder Raina et al.
ANNALS OF INTERNAL MEDICINE (2008)
Current Pharmacologic treatment of dementia: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians
Amir Qaseem et al.
ANNALS OF INTERNAL MEDICINE (2008)
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C→T) with reduced concentrations of unboosted atazanavir
Marco Siccardi et al.
CLINICAL INFECTIOUS DISEASES (2008)
Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry
Ming-Yan Liu et al.
CLINICAL THERAPEUTICS (2008)
Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease
Magdolna Paskaski et al.
NEUROCHEMISTRY INTERNATIONAL (2008)
Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients
G. Lefevre et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Rivastigmine exposure provided by a transdermal patch versus capsules
Francois Mercier et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Memantine:: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutarnatergic system -: too little activation is bad, too much is even worse
Chris G. Parsons et al.
NEUROPHARMACOLOGY (2007)
Opinion - Pathologically activated therapeutics for neuroprotection
Stuart A. Lipton
NATURE REVIEWS NEUROSCIENCE (2007)
The epidemiology of the dementias: an update
Chengxuan Qiu et al.
CURRENT OPINION IN PSYCHIATRY (2007)
Pharmacokinetic rationale for the rivastigmine patch
Jeffrey Cummings et al.
NEUROLOGY (2007)
Nicotinic component of galantamine in the regulation of amyloid precursor protein processing
Silvia C. Lenzken et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2007)
Memantine pharmacotherapy - A naturalistic study using a population pharmacokinetic approach
Johannes Kornhuber et al.
CLINICAL PHARMACOKINETICS (2007)
Pharmacogenetic aspects of therapy with cholinesterase inhibitors: The role of CYP2D6 in Alzheimer's disease pharmacogenetics
Ramon Cacabelos et al.
CURRENT ALZHEIMER RESEARCH (2007)
Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease
Rafael Blesa et al.
PHARMACOGENETICS AND GENOMICS (2006)
The significance of the cholinergic system in the brain during aging and in Alzheimer's disease
R. Schliebs et al.
JOURNAL OF NEURAL TRANSMISSION (2006)
From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain
P. Riederer et al.
JOURNAL OF NEURAL TRANSMISSION (2006)
Relationship between the efficacy of rivastigmine and apolipoprotein E (ε4) in patients with mild to moderately severe Alzheimer disease
Rafael Blesa et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2006)
Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients
Federica Varsaldi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
RM Lane et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2006)
A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer's disease
Denise Harold et al.
PHARMACOGENETICS AND GENOMICS (2006)
Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment
T Dantoine et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2006)
Pharmacokinetic study of memantine in healthy and renally impaired subjects
A Periclou et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Effect of the apolipoprotein E epsilon 4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease
GH Suh et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2006)
Global prevalence of dementia: a Delphi consensus study
CP Ferri et al.
LANCET (2005)
Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers
QY Zhao et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: A single-center, multiple-dose, open-label study
N Rao et al.
CLINICAL THERAPEUTICS (2005)
Responsiveness to cholinesterase inhibitors in Alzheimer's disease: A possible role for the 192 Q/R polymorphism of the PON-1 gene
R Pola et al.
NEUROSCIENCE LETTERS (2005)
A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease
R Raschetti et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects
CP Yao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Apolipoprotein E epsilon 4 allele differentiates the clinical response to donepezil in Alzheimer's disease
A Bizzarro et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2005)
Dementia of Alzheimer's disease and other neurodegenerative disorders - memantine, a new hope
SK Sonkusare et al.
PHARMACOLOGICAL RESEARCH (2005)
The pharmacogenomics of Alzheimer's disease
V Crentsil
AGEING RESEARCH REVIEWS (2004)
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil - A randomized controlled trial
PN Tariot et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines
M Zimmermann et al.
JOURNAL OF NEUROCHEMISTRY (2004)
Memantine hydrochloride -: Pharmacological and clinical profile
HJ Möbius et al.
DRUGS OF TODAY (2004)
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
UM Zanger et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2004)
Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients
JF Reyes et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function
CF Nagy et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers
M Farlow et al.
PHARMACOGENOMICS JOURNAL (2004)
Cholinesterase inhibitors used in the treatment of Alzheimer's disease the relationship between pharmacological effects and clinical efficacy
DG Wilkinson et al.
DRUGS & AGING (2004)
Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions
S Micuda et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)
The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development
AV Terry et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence
W Danysz et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2003)
Memantine for the treatment of dementia
GK Wilcock
LANCET NEUROLOGY (2003)
Galantamine population pharmacokinetics in patients with Alzheimer's disease: Modeling and simulations
V Piotrovsky et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Memantine in moderate-to-severe Alzheimer's disease
B Reisberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Cholinesterases: New roles in brain function and in Alzheimer's disease
E Giacobini
NEUROCHEMICAL RESEARCH (2003)
Clinical pharmacokinetics of galantamine
MR Farlow
CLINICAL PHARMACOKINETICS (2003)
Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine
Z Qin et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Presence or absence of at least one ε4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease
AS Rigaud et al.
PHARMACOGENETICS (2002)
The metabolism and excretion of galantamine in rats, dogs, and humans
GSJ Mannens et al.
DRUG METABOLISM AND DISPOSITION (2002)
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
MW Jann et al.
CLINICAL PHARMACOKINETICS (2002)
Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type
M Hossain et al.
CLINICAL PHARMACOKINETICS (2002)
Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease
JVS Gobburu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2001)
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
B Winblad et al.
NEUROLOGY (2001)
APOE genotype:: No influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease
J Aerssens et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2001)
Selective inhibitors of butyrylcholinesterase - A valid alternative for therapy of Alzheimer's disease?
E Giacobini
DRUGS & AGING (2001)
Pharmacogenetics and adverse drug reactions
UA Meyer
LANCET (2000)
Galantamine - A review of its use in Alzheimer's disease
LJ Scott et al.
DRUGS (2000)
Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease
A Maelicke et al.
BEHAVIOURAL BRAIN RESEARCH (2000)
Galantamine in AD - A 6-month randomized, placebo-controlled trial with a 6-month extension
MA Raskind et al.
NEUROLOGY (2000)
Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease
MW Jann
PHARMACOTHERAPY (2000)
Donepezil therapy in clinical practice - A randomized crossover study
SM Greenberg et al.
ARCHIVES OF NEUROLOGY (2000)
分享论文
